Dhivy Shortage Update: What Patients Need to Know in 2026

If you take Dhivy for Parkinson's disease and you've had trouble finding it at your pharmacy, you're not alone — and your frustration is completely understandable. The broader carbidopa/levodopa landscape has faced significant supply disruptions over the past several years, and navigating it can feel overwhelming.

This article gives you a clear, current picture of Dhivy's availability status in 2026, explains what's causing challenges across the carbidopa/levodopa market, and tells you exactly what you can do to protect your access to treatment.

Is Dhivy Officially in Shortage?

Dhivy (carbidopa/levodopa 25 mg/100 mg functionally scored tablet) is not currently listed on the FDA or ASHP drug shortage lists as of 2026. The product's immediate-release formulation is generally stable, with Avion Pharmaceuticals continuing to manufacture and distribute it.

However, "not in official shortage" does not mean "easy to find everywhere." Dhivy is a brand-name specialty product from a smaller manufacturer, and it is not stocked at every pharmacy. Patients in some regions may need to search multiple pharmacies or order ahead to ensure consistent access.

The Broader Carbidopa/Levodopa Shortage in 2026

While Dhivy's specific formulation is relatively stable, the broader carbidopa/levodopa market has been under serious stress. Here's the breakdown:

• Immediate-release (IR) tablets: Relatively stable. Multiple manufacturers (Teva, Amneal, Sun Pharma, and others) produce IR tablets in 10/100 mg, 25/100 mg, and 25/250 mg strengths. Spot shortages occur at individual pharmacies but overall supply is more reliable.
• Extended-release (ER/CR) tablets: Active shortage. As of early 2026, carbidopa/levodopa extended-release tablets remain on the American Society of Health-System Pharmacists (ASHP) shortage list. Accord Healthcare discontinued the 25/100 mg ER strength entirely. Only the 50/200 mg ER strength remains from Accord.
• Orally disintegrating tablets (ODT): Effectively discontinued. Sun Pharma stopped making carbidopa/levodopa ODT in December 2022. Viatris discontinued their ODT version in 2021. There are currently no generic ODT manufacturers actively supplying the U.S. market.
• Brand ER capsules (Rytary, Crexont): Available but significantly more expensive than generic tablets and typically requiring prior authorization from insurance.

A New 2026 FDA Warning: Vitamin B6 Deficiency

In March 2026, the FDA issued a MedWatch safety warning requiring updated labeling for all carbidopa/levodopa products, including Dhivy. Long-term use of carbidopa/levodopa can deplete vitamin B6 (pyridoxine) levels, and in some cases this has led to seizures that were only resolved after vitamin B6 administration.

If you have been on Dhivy or any carbidopa/levodopa product for an extended period, ask your doctor about monitoring your vitamin B6 levels. This is particularly important for patients on higher doses.

What Is Driving Availability Challenges for Dhivy?

Several forces contribute to Dhivy's variable pharmacy availability:

• Specialty manufacturer and limited distribution: Avion Pharmaceuticals is a specialty company, and Dhivy's distribution network is narrower than major generic manufacturers.
• No generic equivalent: There is no generic version of Dhivy's functionally scored design, meaning patients cannot be automatically substituted to a generic that offers the same dosing precision.
• Growing Parkinson's disease prevalence: The Parkinson's Foundation estimates nearly one million Americans are living with Parkinson's disease — a number expected to rise as the population ages. Greater demand across all carbidopa/levodopa products puts pressure on supply.
• Routine stocking decisions: Pharmacies stock medications based on local demand. In areas where Dhivy is less commonly prescribed, pharmacies may not keep it in regular inventory — requiring you to request a special order.

What Does Dhivy Cost in 2026?

Here is what you can expect to pay for Dhivy in 2026:

• Retail cash price (90 tablets, 25/100 mg): Approximately $405
• With GoodRx coupon (90 tablets): As low as ~$130
• With insurance: Covered by some Medicare Part D and private plans; copay varies by plan and tier
• Avion savings program: Dhivy.com/savings-and-support offers financial support options for eligible patients

For comparison, generic carbidopa/levodopa IR tablets can cost as little as $9 per month with a GoodRx coupon — though they don't replicate Dhivy's precise dosing design.

What You Can Do Right Now

1. Search early — Start your refill search 10–14 days before you need your next supply.
2. Use medfinder — Visit medfinder.com to have pharmacies near you contacted about Dhivy availability, saving you hours of phone calls.
3. Ask your pharmacist to order ahead — Even if your pharmacy doesn't stock it routinely, they can order it from their wholesaler within 1–2 business days.
4. Call your neurologist — If you're at risk of a gap in treatment, contact your prescriber immediately. They can arrange a bridge supply or early refill.
5. Ask about B6 monitoring — Given the new 2026 FDA warning, ask your doctor whether you should have your vitamin B6 levels checked, especially if you've been on carbidopa/levodopa for years.

The Bottom Line

Dhivy itself is not in an official shortage, but its specialized nature means it won't always be on the shelf at your local pharmacy. The key is to plan ahead, use the right tools to locate it, and know your options if you need a temporary alternative. For more information on alternatives, see our guide on alternatives to Dhivy.